Systematic pelvic and aortic lymphadenectomy in advanced ovarian cancer patients at the time of interval debulking surgery: A double-institution case-control study

Annals of Surgical Oncology

Volumn 19, Issue 11, 2012, Pages 3522-3527

  Fagotti, Anna ^a   De Iaco, Pierandrea ^b   Fanfani, Francesco ^a   Vizzielli, Giuseppe ^a   Perelli, Federica ^a   Pozzati, Federica ^b   Perrone, Anna Myriam ^b   Turco, Luigi Carlo ^a   Scambia, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; AORTIC LYMPHADENECTOMY; ARTICLE; BLOOD TRANSFUSION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; OPERATION DURATION; OVARY CANCER; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; POSTOPERATIVE COMPLICATION; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AORTA; BLOOD TRANSFUSION; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; OPERATIVE TIME; OVARIAN NEOPLASMS; PELVIS; RETROSPECTIVE STUDIES;

EID: 84868197051     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2400-9     Document Type: Article

References (24)

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 2.2012. NCCN.org.http://www.nccn. org/professionals/physician-gls/pdf/ovarian. pdf. Accessed 1 Mar 2012.
2. Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: A randomized clinical trial. J Natl Cancer Inst. 2005;97:560-6. (Pubitemid 40723783)
3. Eisenkop SM, Freiedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol. 1998;69:103-8. (Pubitemid 28246994)
4. Schwartz PE. Neoadjuvant chemotherapy for the management of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2002;16: 585-96. (Pubitemid 41123408)
5. Ozols RF. Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. Semin Oncol. 2000;27:47-9. (Pubitemid 30643853)
6. Van Der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med. 1995;332:629-34.
7. Chambers SK. Systematic lymphadenectomy in advanced epithelial ovarian cancer: Two decades of uncertainty resolved. J Natl Cancer Inst. 2005;97:548-9. (Pubitemid 40723775)
8. Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:1238-44. (Pubitemid 350077354)
9. AGO Study Group (AGO-OVAR). Lymphadenectomy in ovarian neoplasms (LION). An open randomized prospective multicenter trial. AGO-OVAR OP.3. NCT00712218. ClinicalTrials.gov.http://clinicaltrials.gov/ct2/show/NCT00712218. Accessed 1 Feb 2012.
10. Du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J. Potential role of lymphadenectomy in advanced ovarian cancer: A combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol. 2010;28:1733-9.
11. Rouzier R, Bergzoll C, Brun JL, et al. The role of lymph node resection in ovarian cancer: Analysis of the surveillance, epidemiology, and end results (SEER) database. BJOG. 2010;117: 1451-8.
12. Joulie F, Morice P, Rey A, et al. Are nodal metastases in ovarian cancer chemoresistant lesions? Comparative study of initial lymphadenectomy or after chemotherapy. Gynecol Obstet Fertil. 2004;32:502-7. (Pubitemid 38813196)
13. Eisenhauer EA, Therasseb P, Bogaertsc J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
14. Gronlund B, Hansen HH, Høgdall C, Høgdall EV, Engelholm SA. Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? Br J Cancer. 2004;90:377-82. (Pubitemid 38250632)
15. Sharma S, Driscoll D, Oduns K, Venkatadri A, Lele S. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. Am J Obstet Gynecol. 2005;193:2077-82. (Pubitemid 41737638)
16. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240: 205-13. (Pubitemid 38963009)
17. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol. 2010;34:433-43.
18. Rose PG, Nerenstone S, Brady MF, et al; Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004;351:2489-97.
19. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-53.
20. Di Re F, Baiocchi G, Fontanelli R, et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: Prognostic significance of node metastases. Gynecol Oncol. 1996;62:360-5. (Pubitemid 26322426)
21. Baiocchi G, Grosso G, di Re E, Fontanelli R, Raspagliesi F, di Re F. Systematic pelvic and paraaortic lymphadenectomy at secondlook laparotomy for ovarian cancer. Gynecol Oncol. 1998;69: 151-6. (Pubitemid 28247002)
22. Scarabelli C, Gallo A, Zarrelli A, Visentin C, Campagnutta E. Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: Potential benefit on survival. Gynecol Oncol. 1995;56:328-37.
23. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol. 1991;40:103-6.
24. Aletti GD, Santillan A, Eisenhauer EL, et al. A new frontier for quality of care in gynecologic oncology surgery: Multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007;107:99-106. (Pubitemid 47464550)